SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Grifols logo outside building in Frankfurt, Germany
Mergers & Acquisitions
Grifols Gets $6B Takeover Offer from Founding Family, Brookfield to Go Private
The blood plasma pharma is considering a buyout offer from the founding family and asset manager Brookfield, which would delist the company from the Spanish and Nasdaq markets.
July 8, 2024
 · 
1 min read
 · 
Kate Goodwin
CAR-T Cells attacking a cell on a blue background
Drug Development
Cartesian Gets Phase II Win in Myasthenia Gravis, Looks to Raise $130M Through Financing
Cartesian Therapeutics’ mRNA CAR-T therapy met its primary endpoint in a mid-stage trial for the chronic autoimmune disorder and expects to raise $130 million via private placement equity financing.
July 2, 2024
 · 
2 min read
 · 
Kate Goodwin
Business
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic
The biotech incubator said Wednesday the majority of the fund will be for clinical proof-of-concept studies, bringing the total funds raised by Curie.Bio to nearly $1 billion.
June 26, 2024
 · 
1 min read
 · 
Kate Goodwin
Policy
FDA Again Hits AbbVie Parkinson’s Treatment With Complete Response Letter
Citing issues with a third-party manufacturer, the FDA has issued another Complete Response Letter to AbbVie rejecting its New Drug Application for ABBV-951, a proposed treatment for motor fluctuations in adults with advanced Parkinson’s disease.
June 25, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Nasdaq headquarters in New York City
Deals
Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq
The combined company began trading Friday under the Nasdaq symbol TECX. A $130 million private placement was also completed, with a cash runway into mid-2027.
June 21, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Signage outside Gilead's headquarters in California
Drug Development
Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Prevention Trial in Women
Gilead Sciences reported zero cases of HIV infection occurred in the lenacapavir candidate group, compared to 16 cases in the Truvada arm and 39 incidents for those treated with Descovy, Gilead’s approved daily PrEP pills.
June 20, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: FDA sign at Washington D.C. headquarters
Policy
Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies After Patient Deaths
Following two deaths due to presumed sepsis, the FDA has placed a partial clinical hold on three trials for Zentalis’ azenosertib including a Phase I in solid tumors, Phase II in platinum-resistant ovarian cancer and Phase II in uterine serous carcinoma.
June 18, 2024
 · 
1 min read
 · 
Kate Goodwin
Sign outside BioNTech's building in Germany
Drug Development
FDA Slaps BioNTech-MediLink ADC With Partial Clinical Hold Due to ‘Significant Risk of Illness’
The hold on BioNTech and MediLink’s antibody-drug conjugate candidate BNT326/YL202 has halted enrollment in a Phase I U.S. trial in patients with non-small cell lung cancer or breast cancer, following multiple deaths.
June 17, 2024
 · 
1 min read
 · 
Kate Goodwin
Business
The 6 Largest Biopharma Layoffs of 2024 So Far
Despite a surge in the financial markets, multiple Big Pharma companies have announced hundreds or even thousands of cuts. Experts hope for a better second half of the year.
June 11, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: FDA sign at Washington D.C. headquarters
FDA
FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder
Approved for patients with low- to intermediate-risk myelodysplastic syndromes, Geron’s Rytelo is the first telomerase inhibitor to hit the market and the company’s first approved drug after 34 years in business.
June 7, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Illustration of liver surrounded by hepa
Drug Development
Vir Seeks to Challenge Gilead With Phase II Hepatitis Delta Data
Vir Biotechnology reported Wednesday that its monoclonal antibody tobevibart, as a monotherapy and in combination with Alynylam-partnered elebsiran, achieved high rates of virologic response at week 24 in patients with chronic hepatitis delta.
June 5, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Drug Development
ASCO24: BMS Eyes First-Line Treatment in Liver Cancer for Opdivo-Yervoy Combo
BMS presented late-stage results on Tuesday at the ASCO annual meeting which showed the combination of Opdivo and Yervoy lowered the risk of death by 21% in patients with unresectable hepatocellular carcinoma, compared to two kinase inhibitors.
June 4, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: GSK's headquarters in London
Policy
GSK Shares Drop 10% After Delaware Court Allows Zantac Lawsuits to Proceed
A Delaware state court ruled that expert witnesses can present scientific evidence in 69,000 cases involving the discontinued heartburn drug Zantac. News of the court ruling Monday wiped roughly $8.9 billion from GSK’s market value.
June 3, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: A colorful brain surrounded by pill bottles/Taylor Tieden for BioSpace
Drug Development
Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments
While more programs now involve candidates with different targets, experts say anti-amyloid therapies will remain a primary player in treating the memory-robbing disease.
May 31, 2024
 · 
6 min read
 · 
Kate Goodwin
Pictured: Novartis' logo outside its building in S
Drug Development
ASCO24: Novartis Leukemia Drug Beats Older Drugs in Phase III Readout
Novartis’ Scemblix posted stronger results with fewer discontinuation rates than both its own Gleevec and a stronger second-generation TKI, positioning it for a potential first-line indication in chronic myeloid leukemia.
May 31, 2024
 · 
2 min read
 · 
Kate Goodwin
Load More